logo-loader
RNS
viewAlliance Pharma PLC

Alliance Pharma PLC - Total Voting Rights

RNS Number : 5387O
Alliance Pharma PLC
01 June 2020
 

For immediate release

1 June 2020

 

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Total Voting Rights

 

Alliance Pharma plc (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

 

As at 29 May 2020 the Company's issued share capital consists of 530,998,538 Ordinary Shares of 1p each.

 

The total number of voting rights in the Company is 530,998,538 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information:

 

Alliance Pharma plc                                                                                                                        + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

 

Buchanan                                                                                                                                         + 44 (0) 20 7466 5000

Mark Court / Hannah Ratcliff

 

Numis Securities Limited                                                                                                               + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black

 

Investec Bank plc                                                                                                                            +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

 

About Alliance Pharma

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com  

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVREAEKFEESEEFA

Quick facts: Alliance Pharma PLC

Price: 71.9

Market: AIM
Market Cap: £381.84 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE